The Function of the Soluble Interleukin 6 (IL-6) Receptor in Vivo: Sensitization of Human Soluble IL-6 Receptor Transgenic Mice Towards IL-6 and Prolongation of the Plasma Half-life of IL-6

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1996 Apr 1

PMID 8666898

Citations 86

Authors

M Peters

S Jacobs

M Ehlers

P Vollmer

J Mullberg

E Wolf

G Brem

K H Meyer zum Buschenfelde

S Rose-John

Affiliations

Soon will be listed here.

Abstract

Interleukin 6 (IL-6) is considered an important mediator of acute inflammatory responses. Moreover, IL-6 functions as a differentiation and growth factor of hematopoietic precursor cells, B cells, T cells, keratinocytes, neuronal cells, osteoclasts, and endothelial cells. IL-6 exhibits its action via a receptor complex consisting of a specific IL-6 receptor (IL-6R) and a signal transducing subunit (gp130). Soluble forms of both receptor components are generated by shedding and are found in patients with various diseases such as acquired immune deficiency syndrome, rheumatoid arthritis, and others. The function of the soluble (s)IL-6R in vivo is unknown. Since human (h)IL-6 acts on human and murine target cells, but murine IL-6 on murine cells only, we constructed transgenic mice expressing the hsIL-6R. We report here that in the presence of hsIL-6R, mice are hypersensitized towards hIL-6, mounting an acute phase protein gene induction at significantly lower IL-6 dosages compared to control animals. Furthermore, in hsIL-6R transgenic mice, the detected acute phase response persists for a longer period of time. The IL-6/IL-6R complex prolongs markedly the Il-6 plasma half-life. Our results reinforce the role of the hsIL-6R as an agonistic protein, help to understand the function of the hsIL-6R in vivo, and highlight the significance of the receptor in the induction of the acute phase response.

Citing Articles

Interleukin-6: Molecular Mechanisms and Therapeutic Perspectives in Atrial Fibrillation.

Yu J, Dong Q, Du Y Curr Med Sci. 2025; .

PMID: 40035997 DOI: 10.1007/s11596-025-00021-7.

Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy.

Tzaban S, Stern O, Zisman E, Eisenberg G, Klein S, Frankenburg S Front Immunol. 2025; 15():1490035.

PMID: 39845971 PMC: 11752881. DOI: 10.3389/fimmu.2024.1490035.

Cross-Sectional and Longitudinal Associations of Serum LRG1 with Severity and Prognosis Among Adult Community-Acquired Pneumonia Patients.

Wang Y, Jiang Y, Xie M, Qi B, Pu K, Du W J Inflamm Res. 2024; 17:7951-7962.

PMID: 39502939 PMC: 11537034. DOI: 10.2147/JIR.S485932.

Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease.

Kamali Z, Esmaeil N, Thio C, Vaez A, Snieder H Genes (Basel). 2024; 15(7).

PMID: 39062668 PMC: 11275426. DOI: 10.3390/genes15070889.

The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions.

Kerkis I, da Silva A, Araldi R Front Immunol. 2024; 15:1400533.

PMID: 39015561 PMC: 11249726. DOI: 10.3389/fimmu.2024.1400533.

References

Stoyan T, Michaelis U, Schooltink H, Van Dam M, Rudolph R, Heinrich P . Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification. Eur J Biochem. 1993; 216(1):239-45. DOI: 10.1111/j.1432-1033.1993.tb18138.x. View

Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y . Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993; 82(4):1120-6. View

Mullberg J, Dittrich E, Graeve L, Gerhartz C, Yasukawa K, Taga T . Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett. 1993; 332(1-2):174-8. DOI: 10.1016/0014-5793(93)80507-q. View

Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y . Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993; 90(24):11924-8. PMC: 48097. DOI: 10.1073/pnas.90.24.11924. View

Kishimoto T, Taga T, Akira S . Cytokine signal transduction. Cell. 1994; 76(2):253-62. DOI: 10.1016/0092-8674(94)90333-6. View

Mullberg J, Oberthur W, Lottspeich F, MEHL E, Dittrich E, Graeve L . The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol. 1994; 152(10):4958-68. View

De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A . Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994; 93(5):2114-9. PMC: 294340. DOI: 10.1172/JCI117206. View

Darnell Jr J, Kerr I, Stark G . Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264(5164):1415-21. DOI: 10.1126/science.8197455. View

Rose-John S, Heinrich P . Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994; 300 ( Pt 2):281-90. PMC: 1138158. DOI: 10.1042/bj3000281. View

10.

Dittrich E, Rose-John S, Gerhartz C, Mullberg J, Stoyan T, Yasukawa K . Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. J Biol Chem. 1994; 269(29):19014-20. View

11.

Ehlers M, Grotzinger J, deHon F, Mullberg J, Brakenhoff J, Liu J . Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol. 1994; 153(4):1744-53. View

12.

Frieling J, van Deuren M, Wijdenes J, van der Meer J, Clement C, van der Linden C . Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis. 1995; 171(2):469-72. DOI: 10.1093/infdis/171.2.469. View

13.

Sui X, Tsuji K, Tanaka R, Tajima S, Muraoka K, Ebihara Y . gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc Natl Acad Sci U S A. 1995; 92(7):2859-63. PMC: 42318. DOI: 10.1073/pnas.92.7.2859. View

14.

Hirota H, Yoshida K, Kishimoto T, Taga T . Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995; 92(11):4862-6. PMC: 41807. DOI: 10.1073/pnas.92.11.4862. View

15.

Mackiewicz A, Wiznerowicz M, Roeb E, Karczewska A, Nowak J, Heinrich P . Soluble interleukin 6 receptor is biologically active in vivo. Cytokine. 1995; 7(2):142-9. DOI: 10.1006/cyto.1995.1019. View

16.

Greenfield E, Shaw S, Gornik S, Banks M . Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest. 1995; 96(3):1238-44. PMC: 185744. DOI: 10.1172/JCI118157. View

17.

Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S . A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci U S A. 1995; 92(21):9570-4. PMC: 40843. DOI: 10.1073/pnas.92.21.9570. View

18.

Ihle J . Cytokine receptor signalling. Nature. 1995; 377(6550):591-4. DOI: 10.1038/377591a0. View

19.

Mackiewicz A, Gorny A, Laciak M, Malicki J, Murawa P, Nowak J . Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther. 1995; 6(6):805-11. DOI: 10.1089/hum.1995.6.6-805. View

20.

Schindler C, Darnell Jr J . Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995; 64:621-51. DOI: 10.1146/annurev.bi.64.070195.003201. View